Rua’s Australian Supplier, Cann Group, Receives GMP Certification for Southern Facility
Rua Bioscience is pleased to share that Cann Group has been granted a GMP licence to manufacture therapeutic goods for its Southern facility (Southern GMP Licence) by Australia’s Therapeutic Goods Administration (TGA).
Shareholders Approve Zalm Therapeutics Share Issue – Set Stage to Accelerate Market Entry and Expand Patient Choice
Rua Bioscience shareholders have overwhelmingly approved the purchase of Zalm, throwing further shareholder weight behind the company’s bid to become New Zealand’s premier medicinal cannabis company.